Mitchell, J. Et Al. 2022. Farber disease clinical impact: Patient reported outcomes as a measure of disease burden. MOLECULAR GENETICS AND METABOLISM , vol.135, no.2 .

Mitchell, J., Harmatz, P., Selim, L., El Din, I. G., Mungan, N., Bulut, F., ... Lampe, C.(2022). Farber disease clinical impact: Patient reported outcomes as a measure of disease burden. MOLECULAR GENETICS AND METABOLISM , vol.135, no.2.

Mitchell, John Et Al. "Farber disease clinical impact: Patient reported outcomes as a measure of disease burden," MOLECULAR GENETICS AND METABOLISM , vol.135, no.2, 2022

Mitchell, John Et Al. "Farber disease clinical impact: Patient reported outcomes as a measure of disease burden." MOLECULAR GENETICS AND METABOLISM , vol.135, no.2, 2022

Mitchell, J. Et Al. (2022) . "Farber disease clinical impact: Patient reported outcomes as a measure of disease burden." MOLECULAR GENETICS AND METABOLISM , vol.135, no.2.

@article{article, author={John Mitchell Et Al. }, title={Farber disease clinical impact: Patient reported outcomes as a measure of disease burden}, journal={MOLECULAR GENETICS AND METABOLISM}, year=2022}